Information de reference pour ce titreAccession Number: | 00003098-200501000-00008.
|
Author: | Boni, Joseph P. PhD; Leister, Cathie MS; Bender, Gregor PharmD; Fitzpatrick, Virginia MS; Twine, Natalie BS; Stover, Jennifer BS; Dorner, Andrew PhD; Immermann, Fred MS; Burczynski, Michael E. PhD
|
Institution: | Department of Clinical Pharmacology, Wyeth Research, Collegeville; Department of Discovery Medicine, Wyeth Research, Cambridge; and Department of Biometrics Research, Wyeth Research, Pearl River, NY.
|
Title: | |
Source: | Clinical Pharmacology & Therapeutics. 77(1):76-89, January 2005.
|
Abstract: | Objective: Our objective was to estimate the pharmacokinetic parameters of CCI-779 and its metabolite, sirolimus, and evaluate associations of exposure parameters with safety and clinical activity. Exposure parameters were also correlated with pharmacogenomic responses in peripheral blood mononuclear cells (PBMCs).
Methods: In this randomized, double-blind, multicenter trial, once-weekly intravenous doses of 25, 75, or 250 mg CCI-779 were administered to patients with advanced renal cancer. Whole blood for CCI-779 and sirolimus concentrations was drawn. Population pharmacokinetic analyses yielded Bayesian-predicted exposure metrics that were correlated with severity and duration of adverse events and survival. PBMC samples taken before and after treatment were examined for pharmacogenomic responses. Ribonucleic acid samples were converted to labeled probes and hybridized to oligonucleotide arrays containing more than 12,600 human sequences.
Results: The final population pharmacokinetic models of CCI-779 and sirolimus included 235 and 305 observations, respectively, from 50 patients. For CCI-779, dose, single versus multiple dose, and body surface area were significant pharmacokinetic covariates. For sirolimus, dose and hematocrit were significant covariates. Age, sex, or race did not influence drug disposition. CCI-779 area under the curve correlated with adverse event severity for thrombocytopenia (P = .007), pruritus (P = .011), and hyperlipemia (P = .040). Exposure (CCI-779 cumulative area under the curve) correlated with a specific subset of gene transcripts in PBMCs following 16 weeks after therapy (P < .001, Spearman correlation).
Conclusions: Concentrations of CCI-779 and sirolimus were adequately described with a population model incorporating factors for dose, attenuated exposure of multiple doses, body surface area, and hematocrit. Correlations with adverse event severity and duration profiles were provided to aid in the detection of treatment-emergent effects. Pharmacogenomic profiling of PBMCs identified altered ribonucleic acid transcript expression levels that correlate with exposure. These transcripts represent potential biomarkers of CCI-779 exposure in peripheral blood.
(C) Mosby-Year Book Inc. 2005. All Rights Reserved.
|
References: | 1. Gibbons JJ, Discafani C, Peterson R, Hernandez R, Skotnicki J, Frost P. The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo. [abstract]. Proc Am Assoc Cancer Res 1999;40:301.
2. Yu K, Toral-Barza L, Discafani C, Zhang W.-G., Skotnicki J, Frost P, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8:249-258.
3. Georerger B, Kerr K, Tang C.-B., Fung K.-M., Powell B, Sutton LN, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001;61:1527-1532.
4. Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001;7:1758-1764.
5. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 1998;98:10314-10319.
6. Shi Y, Gera J, Hu L, Hsu J, Bookstein R, Li W, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2001;62:5027-5034.
7. Vogt PK. PI3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med 2001;7:482-484.
8. Atkins M, Hidalgo M, Stadler WM, Logan T, Dutcher J, Hudes G, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mTOR kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-918.
9. Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 1998;285:1104-1112.
10. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-761.
11. Petricoin EF III, Hackett JL, Lesko LJ, Puri RK, Gutman SI, Chumakov K, et al. Medical applications of microarray technologies: a regulatory science perspective. Nat Gen 2002;32:474-479.
12. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
13. Wigle DA, Jurisica I, Radulovich N, Pintilie M, Rossant J, Liu N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 2002;62:3005-3008.
14. Swanson BN. Delivery of high quality biomarker assays. Dis Markers 2002;18:47-56.
15. Rockett JC, Burczynski ME, Fornace AJ, Herrmann PC, Krawetz SA, Dix DJ. Surrogate tissue analysis: monitoring toxicant exposure and health status of inaccessible tissues through the analysis of accessible tissues and cells. Toxicol Appl Pharmacol 2004;194:189-199.
16. Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, Stadler W, et al. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 2003;63:6069-6075.
17. Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 2003;14:931-937.
18. Beal SL, Sheiner LB, editors. NONMEM user's guides. San Francisco (CA): NONMEM Project Group, University of California at San Francisco; 1992.
19. SAS Institute Inc. SAS language reference, version 8. Cary (NC): SAS Institute Inc; 1999.
20. Pai SM, Shukla UA, Grasela TH, Knupp CA, Dolin R, Valentine FT, et al. Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex. J Clin Pharmacol 1992;32:242-247.
21. Agresti A. An introduction to categorical data analysis: A Wiley-Interscience publication. Hoboken (NJ): John Wiley & Sons; 1996. p. 34-44.
22. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14:1675-1680.
23. Hill AA, Brown EL, Whitley MZ, Tucker-Kellogg G, Hunter CP, Slonim DK. Evaluation of normalization procedures for oligonucleotide array data based on spiked cRNA controls. Genome Biol 2001;2:RESEARCH0055.
24. Parke J, Holford N, Charles B. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999;59:19-29.
25. Ette E. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997;37:486-495.
26. Gene Expression Omnibus Web site. Available from: URL: http://www.ncbi.nlm.nih.gov/proj...- ouverture dans une nouvelle fenêtre. Accessed Aug 24, 2004.
27. Cunningham EB. An inositolphosphate-binding immunophilin, IPBP12. Blood 1999;94:2778-2789.
|
Language: | English.
|
Document Type: | PHARMACODYNAMICS AND DRUG ACTION.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0009-9236
|
NLM Journal Code: | dhr, 0372741
|
Annotation(s) | |
|
|